Perrigo (PRGO) attracted fresh attention after reporting second quarter 2026 results that exceeded analyst earnings and revenue estimates, while reaffirming full year 2026 sales guidance and maintaining its regular quarterly dividend.

At a share price of $12.54, Perrigo has seen a 7 day share price return of 21.63% and a 30 day share price return of 12.06%, yet its 1 year total shareholder return is down 40.38%, indicating recent momentum contrasts with a much weaker longer term record.

If Perrigo’s recent move has you thinking about where else earnings surprises and shifting sentiment could show up, it may be worth scanning 42 healthcare AI stocks.

Perrigo’s share price has bounced hard on a better quarter, yet the longer term record and guided sales decline for 2026 tell a different story. Does the current valuation still leave enough upside to justify that risk?

Most Popular Narrative: 24% Undervalued

The most followed valuation narrative for Perrigo pegs fair value at $16.50, which sits well above the recent $12.54 close and frames the latest rebound as only a partial catch up to that target.

The aging global population and rising consumer interest in self-care and wellness continue to create longer-term demand tailwinds for Perrigo's OTC and nutrition products, providing stable, defensive revenue streams even in periods of macro uncertainty.

Read the complete narrative. Read the complete narrative.

Want to understand why that $16.50 figure holds up under scrutiny? The narrative leans on steady top line assumptions, margin repair from a deep loss position, and a richer future earnings multiple that has to be justified by that turnaround. The exact mix of revenue growth, margin rebuild, and discount rate work together in a way that is not obvious from the headline number alone.

Behind the scenes, analysts in this narrative assume earnings move from a loss of roughly $1.8b to a modest profit by around 2029, while revenues stay broadly flat and the discount rate sits just under 10%. On top of that, the model applies a future P/E that is meaningfully above the broader US pharmaceuticals group, which does a lot of the heavy lifting in getting from today’s price to the $16.50 outcome.

Result: Fair Value of $16.50 (UNDERVALUED)

However, Perrigo still faces weak category consumption and tough infant formula and OTC competition. This could pressure margins and challenge the current undervaluation narrative.

Next Steps

Mixed signals around Perrigo can make it hard to feel confident about the story, so it helps to move quickly and test the numbers yourself. To weigh both the risks and the potential upside in one place, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Perrigo?

If Perrigo has sharpened your focus, do not stop here. A wider watchlist can highlight opportunities you might otherwise miss and help balance your portfolio.

• Scan for potential bargains that pair quality with attractive pricing by checking the 51 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies in the 9 dividend fortresses that offer higher yields with a focus on resilience.
• Reduce portfolio stress by focusing on stability and financial robustness through the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.